Recent advances in CAR-T cell engineering

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CAR-T therapy has produced impressive outcomes, setbacks such as high relapse rates and resi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Hematol Oncol
Huvudupphovsmän: Huang, Ruihao, Li, Xiaoping, He, Yundi, Zhu, Wen, Gao, Lei, Liu, Yao, Gao, Li, Wen, Qin, Zhong, Jiang F., Zhang, Cheng, Zhang, Xi
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2020
Ämnen:
Review
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333410/
https://ncbi.nlm.nih.gov/pubmed/32616000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00910-5
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk